Navigation Links
Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
Date:10/5/2009

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ -- Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations. In its focused efforts to fight heart disease, cancer and other life-threatening diseases, Pharmacogenomics Centre is leveraging Isilon scale-out NAS to significantly increase workflow efficiency and productivity, while reducing storage management from more than 30 hours per week to less than one hour per week.

"We're sequencing targeted segments of patients' DNA to try and identify individual mutations that can cause those patients to respond unexpectedly to specific drug therapies," said Christopher Beck, senior bioinformatician, Pharmacogenomics Centre. "Obviously the data produced by our next-generation sequencers is mission-critical but we are a scientific organization and our main focus is data analysis, not data storage. We simply can't afford the lengthy storage deployment schedules or complex system management hassles that traditional storage offerings require. With Isilon, we've been able to deploy and manage a high-performance, highly scalable, shared storage resource without having to dedicate any IT staff to managing the system."

With Isilon scale-out NAS, Pharmacogenomics Centre has unified both its DNA sequencing and DNA analysis operations onto a single, shared pool of storage, enabling highly concurrent processing of genomic data to increase productivity and speed time-to-results. Additionally, with Isilon's OneFS® operating system providing 'pay as you grow' scalability, Pharmacogenomics Centre can scale both performance and capacity on-demand to meet the dramatic and unpredictable growth of data within its high-throughput sequencing environment.

"Next-generation genetics research is opening entirely new ways of undertaking critical drug discovery research," said Chris Blessington, senior director of marketing and communications, Isilon Systems. "Pharamcogenomics Centre's successful use of Isilon IQ to advance this new era of drug development is demonstrative of the inherent performance, capacity, and manageability advantages of our scale-out NAS solutions for data-rich life sciences organizations."

About Isilon Systems

Isilon Systems (Nasdaq: ISLN) is the proven leader in scale-out NAS. Isilon's clustered storage and data management solutions drive unique business value for customers by maximizing the performance of their mission-critical applications, workflows, and processes. Isilon enables enterprises and research organizations worldwide to manage large and rapidly growing amounts of file-based data in a highly scalable, easy-to-manage, and cost-effective way. Information about Isilon can be found at http://www.isilon.com.

The names of companies mentioned herein are the trademarks of their respective owners.

SOURCE Isilon Systems


'/>"/>
SOURCE Isilon Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
4. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
5. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
8. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
9. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
10. Breakthrough Mapping of Alzheimers Genome Helps ID Four New Suspect Genes
11. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
Breaking Medicine News(10 mins):